- Sections :
- Crime & Public Safety
- Restaurants & Food
- Sports
- More
Categories
Research & Science
Opexa Therapeutics, Inc. has hired Donald Healey, Ph.D., an experienced cell therapy immunologist, to lead the company's research and development efforts.
Opexa Therapeutics, Inc. has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada on April 14.
Beginning March 19, the Houston Museum of Natural Science Wortham IMAX Theatre will be showing 'Hubbel 3D', offering audiences a unique space experience.
Repros Therapeutics Inc. has received verbal confirmation from the FDA to initiate its study of oral Androxal in the treatment of hypogonadal men with Type II Diabetes (T2D) with a Phase IIa trial.
Lexicon Pharmaceuticals, Inc. will present top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome at GASTRO 2009 in London.
Repros Therapeutics has entered into an amendment with the National Institutes of Health (NIH) to its existing exclusive license for Proellex.
The Environmentally Friendly Drilling Systems (EFD) Program, a collaborative project led by the Houston Advanced Research Center, has been awarded the Interstate Oil and Gas Compact Commission's Stewardship Award for Environmental Partnership.
Repros Therapeutics Inc. has announced results from an exploratory, efficacy and safety study of its drug Androxal® in men with secondary hypogonadism who were receiving testosterone replacement treatment.
Repros Therapeutics plans to try to license Proellex to another company.
Lexicon Pharmaceuticals, Inc. has obtained favorable results from its recently completed Phase 1 studies of LX4211 and has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus.
Opexa Therapeutics, Inc. (NASDAQ:OPXA) has announced results from further analysis of it's Phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS).
Repros Therapeutics Inc. has received verbal notice from the United States Food and Drug Administration (FDA) that it’s Investigational New Drug Applications (INDs) for Proellex have been placed on clinical hold for safety reasons.
Opexa Therapeutics, Inc. has entered into an exclusive agreement with Novartis for the further development of it’s stem cell technology.
Lexicon Pharmaceuticals, Inc. has initiated a Phase 2 clinical trial of LX2931 in patients with rheumatoid arthritis.
Lexicon Pharmaceuticals, Inc. has initiated a Phase 2 clinical trial of LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome.
Repros Therapeutics has scheduled an end of Phase II meeting with the Food and Drug Administration for late September 2009 to discuss a Phase III program investigating the use of Proellex in the treatment of endometriosis.
A potentially dangerous hydrogen gas leak cropped up during the fueling of space shuttle Endeavour on Saturday and forced NASA to postpone the launch by at least four days.
Lexicon Pharmaceuticals, Inc. will be giving presentations on two of its clinical-stage drug development programs at the Digestive Disease Week (DDW) conference in Chicago, Illinois on Sunday, May 31, and Monday, June 1.
Opexa Therapeutics, Inc. will present data from the Phase IIb TERMS clinical trial at the upcoming American Academy of Neurology (AAN) 61st Annual Meeting in Seattle.
